NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Core Viewpoint - NeoGenomics, Inc. has successfully resolved its litigation with Natera, as Natera voluntarily dismissed its appeal, leaving the North Carolina District Court's ruling in favor of NeoGenomics intact [1][2]. Legal Outcome - The North Carolina District Court granted NeoGenomics' motion for summary judgment, ruling that Natera's patent claims are invalid due to ineligible subject matter. The court dismissed Natera's claims against NeoGenomics with prejudice and issued a declaratory judgment of invalidity for both asserted patents [2]. Company Focus - Following the dismissal of the litigation, NeoGenomics plans to concentrate on the clinical launch of its RaDaR ST molecular residual disease assay, scheduled for the first quarter of 2026 [3]. Company Overview - NeoGenomics, Inc. is a leading cancer diagnostics company specializing in cancer genetics testing and information services. The company offers a comprehensive range of oncology-focused testing services to oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms [3]. - The company is headquartered in Fort Myers, Florida, and operates a network of CAP-accredited and CLIA-certified laboratories across the United States, as well as a CAP-accredited laboratory in Cambridge, United Kingdom [3].